Cancer of the Pancreas-Actual 5, 10, and 20+Year Survival: The Lucky and Fortunate Few

Avram M Cooperman; Howard Bruckner; Harry Snady; Hillel Hammerman; Andrew Fader; Michael Feld; Frank Golier; Tom Rush; Jerome Siegal; Franklin Kasmin; Seth Cohen; Michael G Wayne; Mazen E Iskandar; Justin G Steele

doi:10.1016/j.suc.2017.09.007

Cancer of the Pancreas-Actual 5, 10, and 20+Year Survival: The Lucky and Fortunate Few

Surg Clin North Am. 2018 Feb;98(1):73-85. doi: 10.1016/j.suc.2017.09.007.

Affiliations

¹ The Pancreas, Biliary and Advanced Laparoscopy Center of New York, 305 Second Avenue, New York, NY 10003, USA. Electronic address: avram.cooperman@gmail.com.
² The Pancreas, Biliary and Advanced Laparoscopy Center of New York, 305 Second Avenue, New York, NY 10003, USA.
³ Division of Surgical Oncology, Mount Sinai Beth Israel, New York, NY, USA.

PMID: 29191279
DOI: 10.1016/j.suc.2017.09.007

Abstract

Cancer of the pancreas (CaP) is a dismal, uncommon, systemic malignancy. This article updates an earlier experience of actual long-term survival of CaP in patients treated between 1991 to 2000, and reviews the literature. Survival is expressed as actual, not projected, survival.

Keywords: 5Fluorouracil, Streptozotocin, Cis-Platinum (FSP); Actual vs actuarial survival; Cancer of the pancreas (CaP); Chemoradiation therapy (CRT); Lead time bias, Selection bias, Length bias; Pancreaticoduodenal resection (PDR).

Publication types

Review

MeSH terms

Follow-Up Studies
Forecasting*
Global Health
Humans
Pancreatic Neoplasms / mortality*
Survival Rate / trends